---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-004378"
form_type: "8-K"
ticker: "LMAT"
cik: "0001158895"
company_name: "LEMAITRE VASCULAR INC"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:34:30.887173+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LeMaitre Q4 sales up 8% organic; EPS $0.25 (-9%); dividend raised 12% to $0.14; $25M buyback authorized

## Summary
- Q4 sales $41.0M (+4% reported, +8% organic); net income $5.6M (-9%); EPS $0.25 (-9%).
- Gross margin 63.6% vs 65.7% (150 bps FX headwind); op income $7.0M (-16%).
- Quarterly dividend raised 12% to $0.14/share, payable March 23 to record March 9.
- Board authorized $25M share repurchase program through Feb 21, 2024.
- Q1 2023 guidance: sales $42.6-45.0M (mid +11% reported, +13% organic); EPS $0.22-0.27.

## SEC filing metadata
- accession: 0001437749-23-004378
- form_type: 8-K
- ticker: LMAT
- cik: 0001158895
- company_name: LEMAITRE VASCULAR INC
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158895/000143774923004378/0001437749-23-004378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158895/000143774923004378/lmat20230223_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-004378
- JSON: https://secwatch.observer/filing/0001437749-23-004378.json
- Plain text: https://secwatch.observer/filing/0001437749-23-004378.txt

## Key facts
- Earnings Releases
  LEMAITRE VASCULAR INC reported the quarter ended December 31, 2022 results: revenue $41.0mm, net income $5.6mm, EPS $0.25. Guidance initiated.
  - Period: the quarter ended December 31, 2022
  - Revenue: $41.0mm
  - Net income: $5.6mm
  - EPS: $0.25
  - Guidance: initiated
  - Result: preliminary results
  source text: implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance. Q4 2022 Financial Results ● Sales $41.0mm, +4% (+8% organic) vs. Q4 2021 ● Op. income $7.0mm, -16% ● Op. margin 17% ● Net income $5.6mm, -9% ● Earnings per diluted share $0.25, -9% ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/1158895/000143774923004378/0001437749-23-004378-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.